ETF Holdings Breakdown of DAWN

DAWN institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	13,484	USD 97,085
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	94,620	USD 681,264
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	63,935	USD 460,332
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	63,935	USD 460,332
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	49,165	USD 353,988
Total =		285,139	USD 2,053,001

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with DAWN

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month Low Following Analyst Downgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday after Needham & Company LLC lowered their price target on the stock from $18.00 to $16.00. Needham & Company LLC currently has a buy rating on the stock. Day One Biopharmaceuticals traded as low […] - 2025-08-07 02:46:44

Allianz Asset Management GmbH Buys Shares of 25,000 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Allianz Asset Management GmbH bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm bought 25,000 shares of the company’s stock, valued at approximately $198,000. A number of other hedge funds have also made changes to their positions in DAWN. Wealth Enhancement […] - 2025-08-05 04:26:54

Arizona State Retirement System Reduces Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Arizona State Retirement System lessened its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 8.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,902 shares of the company’s stock after selling 1,471 shares during the quarter. Arizona State Retirement […] - 2025-07-24 04:38:49

Alps Advisors Inc. Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Alps Advisors Inc. lowered its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 10.1% during the first quarter, HoldingsChannel.com reports. The firm owned 73,343 shares of the company’s stock after selling 8,206 shares during the period. Alps Advisors Inc.’s holdings in Day One Biopharmaceuticals were worth $582,000 at the end […] - 2025-07-15 06:25:18

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $29.00 Average Price Target from Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given a consensus rating of “Buy” by the seven analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-07-14 02:56:48

Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $30.57

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-06-19 02:46:56

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,579 shares of the company’s stock after buying […] - 2025-06-11 05:14:48

Two Sigma Investments LP Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Two Sigma Investments LP lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 271,776 shares of the company’s stock after selling 135,725 shares during the quarter. Two Sigma […] - 2025-05-30 04:51:01

Deutsche Bank AG Buys 35,460 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Deutsche Bank AG raised its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 11.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,920 shares of the company’s stock after buying an additional 35,460 shares during the […] - 2025-05-20 05:12:56

Mariner LLC Sells 10,376 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Mariner LLC lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 47.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,669 shares of the company’s stock after selling 10,376 shares during the period. Mariner LLC’s holdings in Day One Biopharmaceuticals were worth $148,000 as of its most recent filing with […] - 2025-05-08 04:40:46

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Earnings Beat

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $6.99, but opened at $7.52. Day One Biopharmaceuticals shares last traded at $6.64, with a volume of 935,489 shares trading hands. The company reported ($0.35) earnings […] - 2025-05-08 03:12:49

Hsbc Holdings PLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 38,583 shares of the company’s stock, valued at approximately $481,000. Several other hedge funds also […] - 2025-05-07 04:56:57

Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Wells Fargo & Company MN cut its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 8.4% during the 4th quarter, Holdings Channel reports. The firm owned 51,735 shares of the company’s stock after selling 4,744 shares during the period. Wells Fargo & Company MN’s holdings in Day One Biopharmaceuticals were […] - 2025-05-02 04:24:48

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $32.29 Average Target Price from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given an average rating of “Buy” by the eight analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-04-30 02:34:47

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Fmr LLC

Fmr LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,887,467 shares of the company’s stock after purchasing an additional 5,475,087 shares […] - 2025-04-14 05:15:07

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. reduced its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,805 shares of the company’s stock after selling 1,948 shares during the quarter. Corebridge Financial Inc.’s holdings in Day […] - 2025-04-11 05:40:56

Wellington Management Group LLP Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Wellington Management Group LLP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 731,303 shares of the company’s stock after purchasing an additional 9,722 shares during the quarter. Wellington Management […] - 2025-04-10 06:06:51

Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group

Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by The Goldman Sachs Group from $39.00 to $27.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on DAWN. JPMorgan Chase & Co. dropped their […] - 2025-03-26 04:38:43

Charles Schwab Investment Management Inc. Raises Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Charles Schwab Investment Management Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 5.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 535,501 shares of the company’s stock after buying an additional 28,053 shares during the period. Charles Schwab Investment Management Inc.’s […] - 2025-03-25 05:13:03

Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $34.00 at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) had its target price dropped by JPMorgan Chase & Co. from $39.00 to $34.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 273.63% from the company’s current […] - 2025-03-07 04:50:44

Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low Following Weak Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) hit a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $10.06 and last traded at $10.54, with a volume of 436845 shares. The stock had previously closed at $11.82. The company reported ($0.69) earnings […] - 2025-02-27 07:08:59

Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $43.00 Price Target at The Goldman Sachs Group

Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other analysts have also issued reports on DAWN. Needham & Company LLC […] - 2025-02-11 06:28:49

Back to Listing

Disclaimer